We are seeking highly motivated individuals (up to TWO) to be part of an exciting, biologics drug discovery and development company with a clinical focus in inflammation, auto-immunity and oncology.  Elasmogen uses humanised, shark-derived, VNAR single-domain binders (soloMERs), as therapeutic agents. The individuals sought must be capable of applying advanced biologics, antibody and protein engineering techniques (screening, selection and characterisation) to progress lead programmes towards the clinic.

Knowledge and experience of a broad portfolio of immuno-technologies and their application to drug discovery is fundamental to the project.  The successful applicants will have practical knowledge and experience of techniques covering some or all of the following: phage display library build and screening, gene cloning and optimisation, in vitro cell based assays and recombinant protein expression, purification and characterisation.  Ideally the candidates will possess a post-graduate degree in a relevant Life Science discipline or equivalent industry or related experience (5 years +).  Previous working experience in a biotechnology or pharmaceutical company setting would be seen as an advantage.

Salary (and pension package) will be competitive and reflect qualifications and experience.

Informal enquiries are welcome and should be made to either Dr Caroline Barelle (CEO) or Prof Andy Porter (CTO), (email: ; ).

Elasmogen Ltd ( is another successful and multi-award winning spin-out from the University of Aberdeen’s, Scottish Biologics Facility and part of the growing biologics cluster of companies found in the Aberdeen city area.  Elasmogen will become one of the anchor tenants in Opportunity North East’s £40 M Bio-Hub due to open early 2021.

Elasmogen promotes Diversity and Equal Opportunities

Closing date for applications:  CV and covering Letter – 6th March 2020.